|
MARINE
PHARMACOLOGY:
THE
CLINICAL
PIPELINE
|
Compound Name |
Source |
Chemical Class |
Company |
Disease Area |
Status |
|
Compounds targeting ion channels |
| Ziconotide (PrialtTM) |
Cone snail |
Peptide |
Elan |
Chronic pain |
FDA approved 2004, now marketed by
Eisai in the EU |
| GTS-21 |
Nemertine worm |
Anabaseine-derivative |
NIMH (U. Colorado) |
Schizophrenia |
Phase II (Academic) completed |
| GTS-21 |
Nemertine worm |
Anabaseine-derivative |
Comentis |
Alzheimer/
ADHD |
Phase II |
|
Compounds targeting enzymes |
|
Protein kinase inhibitors |
| Bryostatin-1 |
Bryozoan |
Polyketide |
NCI |
Cancer |
No current clinical trials. Potential
interest in Alzheimers |
|
Proteasome inhibitor |
| NPI-0052 |
Bacteria
(Actinomycete) |
Beta-lactone-gamma-lactam |
Nereus |
Cancer |
Phase I |
|
Microtubule-interacting agents |
| Dolastatin-10 |
Sea slug |
Peptide |
NCI/Knoll |
Cancer |
No details shown on NCI site after
2004 |
| ILX-651 |
Sea slug |
Peptide |
Genzyme |
Cancer |
Preclinical as 4/2008, oral
formulation being developed |
| E7389(eribulin) |
Sponge |
Halichondrin B analog |
Eisai |
Cancer |
Phase III for breast cancer USA & EU;
Phase II (USA) NSCLC; Phase II (US/EU) prostate, Phase II (EU)
sarcoma |
| NPI-2358 |
Fungi |
Diketopiperazine |
Nereus |
Cancer |
Phase II |
| TZT-1027(Soblidotin) aka YHI-501 |
Sea slug |
Peptide |
Aska Pharmaceuticals |
Cancer |
Phase I - III (possibly). Linked to
monoclonals (Auristatin PE). |
| E-7974 |
Sponge |
Tripeptide |
Eisai |
Cancer |
Phase I |
|
DNA and transcription interactive agents |
|
Ecteinascidin-743-Trabectedin
(Yondelis®) |
Sea squirt |
Tetrahydroisoquinolone alkaloid |
PharmaMar/
Johnson & Johnson |
Cancer |
Approved by EMEA Sept 2007
Phase III ovarian cancer completed file FDA/EMEA Fall 08
December 2008
Phase II prostate cancer ongoing
Phase II breast/lung cancer ongoing |
|
PM00 104
(Zalypsis®) |
Mollusc/Sponge |
Synthetic alkaloid based on Jorumycin |
PharmaMar |
Cancer |
Late Phase I development |
| VEGF
interacting agent |
|
Plitidepsin
(Aplidin®) |
Sea squirt |
Cyclic depsipeptide |
PharmaMar |
Cancer |
Phase II multiple myeloma completed
Phase II in T-NHL ongoing
Combination studies ongoing |
|
Lysosomotropic and ErbB interacting agent |
| Kahalalide F |
Sea slug/Algae |
Cyclic depsipeptide |
PharmaMar |
Cancer |
Phase II completed in solid tumors.
Evaluated in severe psoriasis |
|
PM02734 (Irvalec®) |
Sea slug |
Depsipeptide |
PharmaMar |
Cancer |
Phase I ongoing
Phase I/II in combination with Erlontinib in lung under implementation |
|
Compounds with unknown mechanism of action |
| IPL-512602 |
Sponge |
Steroid |
Inflazyme/
Orexo pharmaceuticals |
Inflammation/
Asthma |
No further information available.
Probably discontinued |
|
Compounds targeting GPCRs |
| Pseudopterosin A-methyl ether (TMO) |
Soft Coral |
Diterpene glycoside |
Terosin Group Inc./Univ. of CA |
Wound Healing |
Phase II |
Updated 3/30/2009 by A.M.S. Mayer, Ph.D., Pharmacology
Department, CCOM, Midwestern University, Downers Grove, IL
60515, USA, Email:
amayer@midwestern.edu and Keith B.
Glaser, Ph.D., Global
Pharmaceutical R&D, Cancer Research, Abbott Laboratories, Abbott
Park, IL 60064-6121, USA. Email:
Keith.Glaser@abbott.com.
Revised 3/25/2009 by David J. Newman, Ph.D.,
Chief, Natural Products Branch, National Cancer Institute, Frederick,
MD, 21701, USA. Email:
newmand@mail.nih.gov.
Revised 3/23/2009 by Maria del Carmen Cuevas Marchante,
Ph.D.,
PharmaMar
S.A.,Avda. De los Reyes, 1, Pol. Ind. La Mina-Norte, 28770 Colmenar
Viejo, Madrid, Spain. Email:
ccuevas@pharmamar.com
Revised by 3/10/2009 by Barbara Potts, Ph.D., Nereus
Pharmaceuticals, Inc.,San Diego, CA 92121, USA.. Email:
bpotts@nereuspharm.com
Revised 3/18/2009 by Robert S. Jacobs, Ph.D., and Claudia Moya,
Ph.D., University of California Santa Barbara, Santa Barbara, CA
93106-9610, USA. Email:
rsjacobs@chem.ucsb.edu.
Revised 3/25/2009 by William Kem, Ph.D., University of Florida
College of Medicine, Gainesville, FL 32610-0267. Email:
wrkem@UFL.EDU
Revised 3/18/2009 by Alton Kremer, Eisai Medical Research Inc,
Ridgefield Park, NJ 077660. Email:
Alton_Kremer@eisai.com
Copyright
© 2005-2009 Midwestern University. Last Rev. 6/22/2009. Direct questions or comments to
Site
Coordinator
|
